Getlabs, a leader in at-home diagnostics, has announced the addition of GRAIL’s GalleriⓇ multi-cancer early detection test to its suite of diagnostic services. This collaboration aims to make cancer screening more accessible by providing at-home blood draw services for the Galleri test, thereby eliminating the need for clinic visits. The Galleri test is a significant advancement in cancer screening, capable of detecting multiple types of cancer, including pancreatic, esophageal, ovarian, and liver cancers, which currently lack recommended screening methods. The test works by analyzing cell-free DNA (cfDNA) fragments in a blood sample. Early detection is crucial as the 5-year survival rate for localized cancers is 89%, compared to 21% for cancers that have spread. The current screening paradigm in the U.S. covers only five cancer types, making the Galleri test a valuable addition to cancer detection efforts.
Key Insights
- Enhancing Cancer Screening Accessibility: Getlabs’ integration of the Galleri test into its at-home diagnostic services addresses accessibility issues in cancer screening, particularly for individuals with limited healthcare access or logistical challenges.
- Advancement in Early Cancer Detection: The Galleri test represents a significant leap in cancer screening technology, with the potential to detect multiple deadly cancers that currently lack effective screening methods.
- Improving Survival Rates through Early Detection: The ability of the Galleri test to detect cancers at an early stage, when they are more treatable, could significantly improve survival rates.
- Complementing Existing Screening Methods: The Galleri test is intended to be used alongside existing recommended cancer screenings, offering a more comprehensive approach to cancer detection.
Image Source & Credit: PR Newswire